Mobile

A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention

Mise à jour : Il y a 4 ans
Référence : NCT00291902

Femme et Homme

Extrait

Study of SB-681323 (a novel p38 MAPkinase inhibitor) in subjects with documented coronary heart disease (CHD) undergoing elective percutaneous coronary intervention (PCI).

Critère d'inclusion

  • Coronary Heart Disease

Liens